Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Paraproteinemias 2Immunoglobulin Light-chain Amyloidosis 2Papillomavirus Infections 1Intermittent Fasting 1Breast Neoplasms 1

Interventions

Dexamethasone 7ixazomib 3dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Cyclophosphamide 3Calcium Dobesilate 3Bortezomib 3Clinical Protocols 2venetoclax 1siltuximab 1pomalidomide 1isatuximab 1daratumumab 1X-Rays 1Valganciclovir 1Therapeutics 1Specimen Handling 1Polymerase Chain Reaction 1Phantoms, Imaging 1Magnetic Resonance Spectroscopy 1MLN2238 1Ganciclovir 1Foscarnet 1Flow Cytometry 1Biopsy 1Antiviral Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Immunoglobulin Light-chain Amyloidosis × Clinical Protocols × Clear all
NCT04512235 2026-04-07

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

Alexion Pharmaceuticals, Inc.

Phase 3 Active not recruiting
281 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT04504825 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

Alexion Pharmaceuticals, Inc.

Phase 3 Active not recruiting
125 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡